Zymeworks Inc. announced that the FDA granted accelerated approval for Ziihera (zanidatamab-hrii) to treat adults with previously-treated, unresectable or metastatic HER2-positive biliary tract cancer, earning a $25 million milestone payment and potential future payments totaling up to $1.36 billion.